^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | vepdegestrant (ARV-471) (Ubiquitin pathway modulator, Estrogen receptor alpha degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
205P - VERITAC update: phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ID 409)
Published date:
05/07/2023
Excerpt:
CBR with ARV-471 200 mg QD was 37.1% (95% CI: 21–55) in all evaluable pts (n=35) and 47.4% (95% CI: 24–71)…CBR with ARV-471 200 mg QD was 37.1% (95% CI: 21–55) in all evaluable pts (n=35) and 47.4% (95% CI: 24–71)...After longer follow-up, ARV-471 200 mg QD continued to show clinical activity and was well tolerated in heavily pretreated pts with ER+/HER2- advanced breast cancer.
Trial ID:
Source:
Title:
ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study
Published date:
11/22/2022
Excerpt:
In VERITAC, ARV-471 monotherapy was administered at doses of 200 mg once daily (QD) or 500 mg QD to patients with ER+/HER2- locally advanced/metastatic breast cancer….CBR was 37.1% (95% CI: 21–55) in 35 evaluable patients treated at 200 mg QD and 38.9% (95% CI: 23– 57) in 36 evaluable patients treated at 500 mg QD. CBR in evaluable patients with mutant ESR1 in the 200 mg QD (n=19) and 500 mg QD (n=22) cohorts was 47.4% (95% CI: 24–71) and 54.5% (95% CI: 32–76), respectively....In the phase 2 VERITAC expansion cohorts of patients with ER+/HER2- locally advanced/metastatic breast cancer and prior CDK4/6 inhibitor treatment, ARV-471 monotherapy showed evidence of clinical activity based on CBR, which was further enhanced in the subgroup with ESR1 mutations.
Source:
Title:
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
Published date:
12/14/2020
Excerpt:
As of the data cut-off date of November 11, 2020, 21 adult patients with locally advanced or metastatic ER+/HER2- breast cancer completed at least one treatment cycle with ARV-471 (orally, once-daily) in the Phase 1 clinical trial...one patient in the ARV-471 trial had a confirmed PR with a 51% reduction in target lesion size as assessed by RECIST. Two additional patients had unconfirmed PRs and one additional patient demonstrated stable disease with >50% target lesion shrinkage…Five of 12 patients (42%) achieved CBR (CBR defined as PRs + complete responses + stable disease at 6 months).
